Quantumzyme Corp. (OTC: QTZM) announced today the publication of its latest research in the Journal of Molecular Graphics & Modelling, detailing a fully in silico enzyme engineering approach for designing and evaluating biocatalysts prior to laboratory validation. The study, which focuses on transaminase enzyme variants used in the asymmetric synthesis of L-HPE—a chiral intermediate relevant to certain ACE inhibitor drug manufacturing processes—examines whether enzyme variants can be computationally optimized before experimental testing.
Rather than relying exclusively on traditional experimental iteration, the research employed large-scale virtual screening and computational modeling techniques to assess enzyme–substrate interactions, catalytic alignment, and structural stability under defined simulation conditions. This approach enabled the identification of enzyme candidates for subsequent experimental consideration, potentially reducing the time and cost associated with biocatalyst development.
“Publishing this research in the Journal of Molecular Graphics & Modelling represents an important scientific milestone for Quantumzyme,” said Naveen Kulkarni, Chief Executive Officer. “This study contributes to the growing body of evidence supporting computational enzyme engineering as a complementary tool in biocatalyst development. At Quantumzyme, we are focused on integrating computational modeling with experimental workflows. By evaluating enzyme variants virtually prior to laboratory testing, we aim to improve research efficiency and better inform downstream validation efforts.”
The study underscores the expanding role of computational modeling in biocatalysis research. By supporting early-stage evaluation and hypothesis testing, in silico methodologies may help reduce experimental iteration and improve the prioritization of enzyme candidates for laboratory study. However, the publication does not represent regulatory approval, commercial validation, or confirmation of manufacturing readiness. Additional experimental testing, optimization, and scale-up would be required before any potential industrial application.
In a separate update, Quantumzyme announced that the Financial Industry Regulatory Authority (FINRA) has received all necessary information to complete its review of the Company’s previously announced corporate name change and corresponding trading symbol request. Based on current communications, the Company anticipates that, subject to FINRA’s final approval, the name change and new trading symbol are expected in the coming days. Regulatory processes remain outside of the Company’s control, and no assurance can be given regarding the exact timing or approval of the request. Upon effectiveness, the Company intends to issue a separate announcement confirming the official name and ticker symbol change.
For more information, visit www.quantumzymecorp.com and the Company’s profile at www.otcmarkets.com/stock/QTZM.
